治疗开始阶段左旋多巴副作用的发生率。
Incidence of side effects from levodopa during the introduction of treatment.
作者信息
Godwin-Austen R B, Frears C C, Bergmann S
出版信息
Br Med J. 1971 Jan 30;1(5743):267-8. doi: 10.1136/bmj.1.5743.267.
Abstract
Twenty patients with Parkinsonism were investigated in order to establish whether the gradual introduction of treatment with levodopa allows a higher dose to be tolerated than can be achieved if treatment is introduced rapidly. No indication was obtained that slow introduction of treatment offers an advantage in maximum tolerated dose, and patients aged 65 and over responded similarly in this respect to those under 65. The maximum tolerated dose is slightly lower in the elderly patient. The incidence of the different side effects does not appear to be affected by the rate of increasing the dose of levodopa.
摘要
对20名帕金森病患者进行了调查，以确定与快速开始治疗相比，逐渐引入左旋多巴治疗是否能使患者耐受更高的剂量。没有迹象表明缓慢开始治疗在最大耐受剂量方面具有优势，65岁及以上的患者在这方面的反应与65岁以下的患者相似。老年患者的最大耐受剂量略低。左旋多巴剂量增加的速度似乎不会影响不同副作用的发生率。
相似文献
1
Incidence of side effects from levodopa during the introduction of treatment.治疗开始阶段左旋多巴副作用的发生率。
Br Med J. 1971 Jan 30;1(5743):267-8. doi: 10.1136/bmj.1.5743.267.
2
Sickness due to levodopa-induced neck dyskinesias in Parkinson's disease.帕金森病中左旋多巴诱发的颈部运动障碍所致疾病。
Mov Disord. 1991;6(1):91-2. doi: 10.1002/mds.870060122.
3
Does tolerance develop to levodopa? Comparison of 2- and 21-H levodopa infusions.左旋多巴会产生耐受性吗？2小时与21小时左旋多巴输注的比较。
Mov Disord. 1993 Apr;8(2):139-43. doi: 10.1002/mds.870080204.
4
The Sydney Multicentre Study of Parkinson's disease: a report on the first 3 years.悉尼帕金森病多中心研究：头3年的报告
J Neurol Neurosurg Psychiatry. 1989 Mar;52(3):324-8. doi: 10.1136/jnnp.52.3.324.
5
Motor response complications with chronic levodopa therapy.慢性左旋多巴治疗的运动反应并发症
Adv Neurol. 1990;53:377-81.
6
Temporary levodopa withdrawal.
N Engl J Med. 1986 Mar 27;314(13):851-3. doi: 10.1056/NEJM198603273141314.
7
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group.帕金森病中速释与控释卡比多巴/左旋多巴的比较。一项多中心5年研究。CR首次研究组。
Eur Neurol. 1997;37(1):23-7. doi: 10.1159/000117399.
8
Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.恩他卡朋对帕金森病波动型和非波动型患者均有益：一项随机、安慰剂对照、双盲、为期六个月的研究。
J Neurol Neurosurg Psychiatry. 2003 Aug;74(8):1071-9. doi: 10.1136/jnnp.74.8.1071.
9
Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.皮下注射阿扑吗啡用于对口服治疗有精神副作用的帕金森病患者。
J Neurol Neurosurg Psychiatry. 1991 Apr;54(4):372-3. doi: 10.1136/jnnp.54.4.372.
10
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.盐酸多奈哌齐与左旋多巴/卡比多巴联合用于帕金森病患者：多次口服给药后药代动力学变化及安全性评估
Br J Clin Pharmacol. 2004 Nov;58 Suppl 1(Suppl 1):41-9. doi: 10.1111/j.1365-2125.2004.01799.x.
引用本文的文献
1
Literature-Based Discovery Predicts Antihistamines Are a Promising Repurposed Adjuvant Therapy for Parkinson's Disease.基于文献的发现表明抗组胺药是一种有前途的帕金森病辅助治疗药物。
Int J Mol Sci. 2023 Aug 2;24(15):12339. doi: 10.3390/ijms241512339.
2
A risk-benefit assessment of drugs used in the management of Parkinson's disease.帕金森病治疗用药的风险效益评估
Drug Saf. 1994 Aug;11(2):94-103. doi: 10.2165/00002018-199411020-00004.
3
Effect of age and arteriosclerosis on the response of Parkinsonian patients to levodopa.年龄和动脉硬化对帕金森病患者左旋多巴反应的影响。
Br Med J. 1971 Nov 27;4(5786):522-4. doi: 10.1136/bmj.4.5786.522.
4
[Differential treatment of Parkinson's disease, with special reference to the possibility of iatrogenic disorders (author's transl)].帕金森病的鉴别治疗，特别提及医源性疾病的可能性（作者译）
Arch Psychiatr Nervenkr (1970). 1974 Apr 9;218(4):319-38. doi: 10.1007/BF00342576.
5
The comparative value of amantadine and levodopa.金刚烷胺与左旋多巴的比较价值。
Postgrad Med J. 1972 Jun;48(560):354-8.
6
Treatment of chronic hepatic encephalopathy with levodopa.左旋多巴治疗慢性肝性脑病
Gut. 1974 Jul;15(7):555-61. doi: 10.1136/gut.15.7.555.
7
Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.左旋多巴：对其药理特性及治疗用途的综述，特别提及帕金森病
Drugs. 1971;2(4):262-400. doi: 10.2165/00003495-197102040-00002.
8
The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa.年龄对单独使用左旋多巴以及在卡比多巴存在情况下左旋多巴药代动力学的影响。
Br J Clin Pharmacol. 1989 Jul;28(1):61-9. doi: 10.1111/j.1365-2125.1989.tb03506.x.
9
Pain as a major cause of postoperative nausea.疼痛是术后恶心的主要原因。
Can Anaesth Soc J. 1976 Jul;23(4):366-9. doi: 10.1007/BF03005916.
本文引用的文献
1
Miosis during L-dopa therapy.左旋多巴治疗期间的瞳孔缩小。
Br Med J. 1970 Jun 13;2(5710):639-40. doi: 10.1136/bmj.2.5710.639.
2
Treatment of parkinsonism with L-dopa (study of 105 patients).左旋多巴治疗帕金森综合征（105例患者的研究）。
Dis Nerv Syst. 1969 Nov;30(11):737-46.
3
Aromatic amino acids and modification of parkinsonism.芳香族氨基酸与帕金森病的修饰
N Engl J Med. 1967 Feb 16;276(7):374-9. doi: 10.1056/NEJM196702162760703.
4
Hypotension caused by L-dopa.左旋多巴引起的低血压。
Br Med J. 1970 Feb 21;1(5694):474-5. doi: 10.1136/bmj.1.5694.474.
5
L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.左旋多巴（L-3,4-二羟基苯丙氨酸）——其在帕金森病中的临床疗效。
Trans Am Neurol Assoc. 1968;93:56-63.
6
Mydriatic responses to sympathomimetic amines in patients treated with L-dopa.左旋多巴治疗患者对拟交感神经胺的散瞳反应。
Lancet. 1969 Nov 15;2(7629):1043-4. doi: 10.1016/s0140-6736(69)90646-1.
7
L-dopa in idiopathic parkinsonism.
Lancet. 1969 Nov 8;2(7628):973-6. doi: 10.1016/s0140-6736(69)90536-4.
8
Effects of L-dopa in Parkinson's disease.
Lancet. 1969 Jul 26;2(7613):165-8. doi: 10.1016/s0140-6736(69)91417-2.
9
L-dopa in postencephalitic parkinsonism.左旋多巴用于脑炎后帕金森综合征。
Lancet. 1969 Apr 12;1(7598):744-6. doi: 10.1016/s0140-6736(69)91751-6.
10
Modification of Parkinsonism--chronic treatment with L-dopa.帕金森病的改善——左旋多巴的长期治疗
N Engl J Med. 1969 Feb 13;280(7):337-45. doi: 10.1056/NEJM196902132800701.
Zotero 插件